National Institutes of Health · Department of Health and Human Services
Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
Key facts
- Deadline
- Forecast — the expected date (Oct 5, 2026) has passed; watch for the official notice
- Award size
- Not specified — see notice
- Cost share / match ?
- Not required
- Who can apply
- Other (see eligibility), Small business, Public college or university, Private college or university, Nonprofit without 501(c)(3), Special district (utility, fire, etc.), Larger business, Tribal government, County government, Nonprofit with 501(c)(3), Tribal organization, City or town government, State government, School district
- Where
- Anywhere in the U.S., including Tennessee
Before you apply: federal grants require an active SAM.gov registration (Unique Entity ID) and a Grants.gov account. Registration is free but can take weeks, so start now, not when the deadline is close. Grant-ready checklist
How this fits you
- Available in Tennessee (nationwide program)
- No cost share required
- Tennessee recipients since 2023: 20
Tell us who you are to see whether you're eligible.
More from National Institutes of Health
- Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed) · Forecast — the expected date (Jul 15, 2025) has passed; watch for the official notice
- IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed) · Forecast — the expected date (Jul 15, 2025) has passed; watch for the official notice
- Forecast to Renew the Notice of Funding Opportunity Announcement for the Multiple Chronic Disease Research Centers · Forecast — the expected date (Jul 25, 2025) has passed; watch for the official notice
- Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed) · Forecast — the expected date (Aug 22, 2025) has passed; watch for the official notice
- Forecast to Publish a Funding Opportunity Announcement for the Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Administrative Resource (Collaborative U24 - Clinical Trials not allowed) · Forecast — the expected date (Sep 30, 2025) has passed; watch for the official notice
- Forecast to Publish a Funding Opportunity Announcement for the Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Research Resource (Collaborative U24 - Clinical Trials not allowed) · Forecast — the expected date (Sep 30, 2025) has passed; watch for the official notice
Official notice: https://simpler.grants.gov/opportunity/99c20e3e-db22-4aba-9a35-60ec39849620 · Printed from grantme.click/grants/d26842cc-0546-4716-a70f-f2a73b6e23e8
Read the official notice View on Grants.gov Sign in to save
About this grant
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on Alzheimer's disease (AD) and AD-related dementias (ADRD) drug target validation and early-stage drug discovery against novel targets. This NOFO will utilize the U01 activity code. The NOFO will support rigorous preclinical AD/ADRD drug target validation and early-stage drug discovery of small molecules, biologic, and emerging therapeutic modalities. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into AD/ADRD and drug discovery are encouraged to begin to consider applying for this new NOFO.
Eligibility (from the notice)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Who in Tennessee has won this program
20 awards to Tennessee recipients in 3 counties since federal FY2023. Largest shown:
| Recipient | Where | Amount | FY |
|---|---|---|---|
| Vanderbilt University Medical Center | Nashville, Davidson County | $37.5M | 2021 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $24.1M | 2011 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $18.6M | 2024 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $18.3M | 2019 |
| St Jude Children'S Research Hospital Inc | Memphis, Shelby County | $14.9M | 2015 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $10M | 2025 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $7.3M | 2011 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $6.9M | 2015 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $6.6M | 2024 |
| University Of Tennessee | Memphis, Shelby County | $6.1M | 2021 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $5.9M | 2019 |
| Vanderbilt University Medical Center | Nashville, Davidson County | $5.6M | 2020 |
Source: USAspending.gov. Past awards show who this program funds; they don't guarantee future awards.
About the program (93.866)
Aging Research — (Aging)
How applications are judged
The major elements in evaluating proposals include assessments of: the scientific merit and general significance of the proposed study and its objectives; the technical adequacy of the experimental design and approach; the competency of the proposed investigator or group to successfully pursue the project; the adequacy of the available and proposed facilities and resources; the necessity of the budget components requested in relation to the proposed project; and the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed...
Matching requirements
This program has no statutory formula.
Matching requirements are not applicable to this assistance listing.
MOE requirements are not applicable to this assistance listing.
Examples of funded projects
Not Applicable.